This report's brief history of layoffs definitely repeats lessons of the past, such as those gleaned in 2009 when the Merck/Schering-Plough and Pfizer/Wyeth mergers triggered enormous workforce reductions. Sanofi kept the theme of merger-related layoffs alive in 2011 with cuts associated with its blockbuster buyout of Genzyme last year, but, of course, many of the French drug giant's former workers have generic threats to blood thinner Plavix to blame for their pink slips. (Más)
01. Merck 12/13.000
02. Pfizer 4.220
03. Novartis 2.000
04. Abbott Laboratories 1.900
05. AstraZeneca 1.550
06. Teva Pharmaceutical 200 (Rumored adittional cuts 1.000/1.500)
07. Sanofi 700
08. Johnson & Johnson 1.000
09. Eisai 600 (USA) / 300 (international)
10. Bayer 540
Click sobre cada compañía para ver detalles
Ver también:
Entradas
No hay comentarios:
Publicar un comentario